File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.kint.2022.07.018
- WOS: WOS:000889512200010
Supplementary
-
Citations:
- Web of Science: 0
- Appears in Collections:
Article: The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases
Title | The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases |
---|---|
Authors | |
Issue Date | 2022 |
Citation | Kidney International, 2022 How to Cite? |
Abstract | The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a serious threat to individuals with underlying chronic kidney disease (CKD). People with CKD are immunocompromised and therefore result in poorer outcomes including increased risk of hospitalization and mortality after COVID-19.1 Despite the availability of COVID-19 vaccines, current data on the vaccine efficacy in individuals with CKD are limited to surrogate endpoints such as antibody titers. As a result, a dedicated study is required to evaluate the effectiveness and safety of COVID-19 vaccines for the CKD population. In Hong Kong Special Administrative Region, China, a territory-wide vaccination program with BNT162b2 (Comirnaty; BioNTech/Pfizer/Fosun) and CoronaVac (CoronaVac Life Sciences) commenced on March 6, 2021, and February 23, 2021, respectively. BNT162b2 vaccine was the first SARS-CoV-2 mRNA vaccine approved by the US Food and Drug Administration,2 whereas CoronaVac is an inactivated whole-virion SARS-CoV-2 vaccine using adjuvant aluminum hydroxide.3 Using territory-wide electronic medical records and vaccination records, we conducted this population-based, retrospective study to evaluate the effectiveness and safety of COVID-19 vaccines in the CKD population. |
Persistent Identifier | http://hdl.handle.net/10722/316755 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cheng, WTF | - |
dc.contributor.author | FAN, M | - |
dc.contributor.author | Wong, CKH | - |
dc.contributor.author | Chui, SLC | - |
dc.contributor.author | Lai, TTF | - |
dc.contributor.author | Li, X | - |
dc.contributor.author | Wan, YFE | - |
dc.contributor.author | Tang, SCW | - |
dc.contributor.author | Chan, EWY | - |
dc.contributor.author | Wong, ICK | - |
dc.date.accessioned | 2022-09-16T07:22:49Z | - |
dc.date.available | 2022-09-16T07:22:49Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Kidney International, 2022 | - |
dc.identifier.uri | http://hdl.handle.net/10722/316755 | - |
dc.description.abstract | The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a serious threat to individuals with underlying chronic kidney disease (CKD). People with CKD are immunocompromised and therefore result in poorer outcomes including increased risk of hospitalization and mortality after COVID-19.1 Despite the availability of COVID-19 vaccines, current data on the vaccine efficacy in individuals with CKD are limited to surrogate endpoints such as antibody titers. As a result, a dedicated study is required to evaluate the effectiveness and safety of COVID-19 vaccines for the CKD population. In Hong Kong Special Administrative Region, China, a territory-wide vaccination program with BNT162b2 (Comirnaty; BioNTech/Pfizer/Fosun) and CoronaVac (CoronaVac Life Sciences) commenced on March 6, 2021, and February 23, 2021, respectively. BNT162b2 vaccine was the first SARS-CoV-2 mRNA vaccine approved by the US Food and Drug Administration,2 whereas CoronaVac is an inactivated whole-virion SARS-CoV-2 vaccine using adjuvant aluminum hydroxide.3 Using territory-wide electronic medical records and vaccination records, we conducted this population-based, retrospective study to evaluate the effectiveness and safety of COVID-19 vaccines in the CKD population. | - |
dc.language | eng | - |
dc.relation.ispartof | Kidney International | - |
dc.title | The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases | - |
dc.type | Article | - |
dc.identifier.email | Cheng, WTF: francowt@hku.hk | - |
dc.identifier.email | Wong, CKH: carlosho@hku.hk | - |
dc.identifier.email | Chui, SLC: cslchui@hku.hk | - |
dc.identifier.email | Lai, TTF: fttlai@hku.hk | - |
dc.identifier.email | Li, X: sxueli@hku.hk | - |
dc.identifier.email | Wan, YFE: yfwan@hku.hk | - |
dc.identifier.email | Tang, SCW: scwtang@hku.hk | - |
dc.identifier.email | Chan, EWY: ewchan@hku.hk | - |
dc.identifier.email | Wong, ICK: wongick@hku.hk | - |
dc.identifier.authority | Wong, CKH=rp01931 | - |
dc.identifier.authority | Chui, SLC=rp02527 | - |
dc.identifier.authority | Lai, TTF=rp02802 | - |
dc.identifier.authority | Li, X=rp02531 | - |
dc.identifier.authority | Wan, YFE=rp02518 | - |
dc.identifier.authority | Tang, SCW=rp00480 | - |
dc.identifier.authority | Chan, EWY=rp01587 | - |
dc.identifier.authority | Wong, ICK=rp01480 | - |
dc.identifier.doi | 10.1016/j.kint.2022.07.018 | - |
dc.identifier.hkuros | 336392 | - |
dc.identifier.isi | WOS:000889512200010 | - |